Oct 21, 2020 10:53AM

Sep 8, 2020 08:38AM

Aug 27, 2020 08:00AM

Jun 17, 2020 08:00AM

May 18, 2020 08:00AM

Apr 27, 2020 08:00AM

Mar 23, 2020 08:05AM Cyclo Therapeutics Inc. Announces Positive Safety Profile of Its Drug Trappsol® Cyclo™ in the Treatment of Niemann Pick Disease Type C

Mar 2, 2020 08:00AM

Feb 26, 2020 08:00AM

Feb 20, 2020 08:00AM

Feb 11, 2020 08:13AM

Dec 18, 2019 07:00AM

Dec 16, 2019 08:00AM

Dec 10, 2019 05:10AM Cyclo Therapeutics’ Chief Scientific Officer Appointed to President’s Council of Advisors on Science and Technology

Oct 31, 2019 08:00AM

Oct 30, 2019 08:00AM

Sep 27, 2019 10:23AM

Sep 13, 2019 08:00AM

Aug 15, 2019 08:00AM

Aug 13, 2019 08:00AM

Jul 31, 2019 09:28AM CTD Announces Support and Participation at Annual Family Conference of National Niemann-Pick Disease Foundation

Jul 11, 2019 11:05AM

Jun 10, 2019 08:00AM

Mar 14, 2019 08:00AM

Feb 7, 2019 08:00AM

Jan 18, 2019 08:05AM

Jan 18, 2019 08:00AM

Nov 8, 2018 03:07PM CTD Announces Partnership with Synteract to support the Extension Protocol for its Phase I Clinical Trial in the United States

Oct 9, 2018 12:03PM

Oct 5, 2018 08:04AM

Oct 5, 2018 08:00AM

Aug 30, 2018 12:13PM

Aug 30, 2018 12:11PM

Aug 23, 2018 08:00AM

Apr 30, 2018 08:00AM FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol(R) Cyclo(TM) Trial for Niemann-Pick Disease Type C

Mar 12, 2018 09:04AM

Dec 6, 2017 08:00AM

Sep 28, 2017 08:00AM

Sep 18, 2017 08:00AM

Jul 19, 2017 08:00AM

Jun 27, 2017 08:00AM

Jun 21, 2017 08:00AM CTD Holdings Enrolls First Patient in European Phase I/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C

Apr 19, 2017 11:42AM

Apr 10, 2017 02:52PM

Mar 23, 2017 08:00AM

Mar 21, 2017 08:00AM

Jan 17, 2017 08:00AM

325,142 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All